Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder Cancer.
Contieri R, Martini A, Beijert IJ, Mertens LS, Hentschel AE, Bründl J, Compérat EM, Plass K, Rodríguez O, Subiela Henríquez JD, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, Čapoun O, Bauerová L, Pešl M, Maxim Bruins H, Runneboom W, Herdegen S, Breyer J, Brisuda A, Calatrava A, Rubio-Briones J, Seles M, Mannweiler S, Bosschieter J, Kusuma VRM, Ashabere D, Huebner N, Seisen T, Claps F, Masson-Lecomte A, Liedberg F, Cohen D, Lunelli L, Cussenot O, Sheikh SE, Volanis D, Côté JF, Rouprêt M, Haitel A, Shariat SF, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, de Kaa CAH, van der Heijden AG, Kiemeney LALM, Soukup V, Molinaro L, Hurle R, Paciotti M, Moschini M, Pradere B, Perdonà S, Gontero P, Llorente C, Algaba F, Palou J, N'Dow J, Ribal MJ, van der Kwast TH, Babjuk M, Sylvester RJ, van Rhijn BWG.
Contieri R, et al. Among authors: n dow j.
Eur Urol Oncol. 2025 May 20:S2588-9311(25)00104-X. doi: 10.1016/j.euo.2025.04.010. Online ahead of print.
Eur Urol Oncol. 2025.
PMID: 40399193